Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

29,776 signal articles · 60 in last 24h · 148,360 total before filter · latest 40m ago
60last 24h
975last 7d
109● bullish (7d)
123● bearish (7d)
212publishers
AllMacro370Earnings115M&A99Regulatory8Product11Analyst10
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearishshow all (incl. clickbait)
Want in on Anthropic Before the IPO? Buy These 8 Stocks
Benzinga7d agobullish
Want in on Anthropic Before the IPO? Buy These 8 Stocks

Anthropic is barreling toward what could be the largest IPO in history, with investors and bankers reportedly targeting a valuation near $2 trillion and a raise exceeding $86 billion when the offering launches as soon as mid-October — but retail...

The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’
TipRanks11d agobullish
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’

The past several years saw muted IPO activity, a generally negative signal for market health. But 2026 has reversed that trend. Yes, you can say that the June IPO of SpaceX, the largest ever public offering, which raised over $85 billion in funding for Musk’s private space launch company, has accounted for the bulk of the first half’s IPO activity, but that is only part of the story. Even if you strip out SpaceX, the first half of this year saw new ‘traditional’ initial public offerings generate

Investing.com19d agobullish
Jefferies starts biopharma firm Braveheart at Buy after IPO

Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock’s prior closing price. The move comes after the company priced its initial public offering (IPO) at $18 per share earlier this month, raising $382.5 million in one of the largest biotech debuts of 2026.

Solstice (SOLS) Jumps 12.8% on Merger Exit, $500M Buyback
Insider Monkey21d agobullish
Solstice (SOLS) Jumps 12.8% on Merger Exit, $500M Buyback

Solstice Advanced Materials (NASDAQ:SOLS) jumped by 12.76 percent on Friday to finish at $63.53 apiece after abandoning a plan to acquire Element Solutions for $14.5 billion, while investors also cheered a $500 million share buyback program. In a statement, the company said that it entered into an agreement with Element Solutions to formally terminate their […]

Solstice Stock Jumps After Calling Off a Major Acquisition
Barrons.com22d agobullish
Solstice Stock Jumps After Calling Off a Major Acquisition

Shares of Solstice Advanced Materials soared early Friday after the company called off a dramatic acquisition that would have turned the company into even more of an AI play. In early July, Solstice announced a cash and stock deal to buy Element Solutions Element makes products used in semiconductor manufacturing. Together, the companies would supply three legs of the AI value chain: The chips, the data centers, and the power that makes everything work.

Generate Biomedicines stock jumps as post-IPO lock-up set to expire
Proactive25d agobullish
Generate Biomedicines stock jumps as post-IPO lock-up set to expire

Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends Wednesday, will free company insiders, early investors and major shareholders to sell shares...